Medindia

X

High Demand Exists for a Drug That Offers Profound Improvement in Efficacy Over Remicade for Treatment of Acute Ulcerative Colitis

Monday, August 27, 2007 General News J E 4
Advertisement
WALTHAM, Mass., Aug. 27 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that there is a significant opportunity for a drugthat can offer profound improvement in efficacy over Centocor/Schering-Plough/Tanabe's Remicade for the treatment of acute ulcerative colitis.According to the new report entitled Lack of Alternatives to Invasive SurgerySignals Opportunity for Drug Makers: An Acute Ulcerative Colitis Study, anagent that improves on Remicade's efficacy must also offer more convenientadministration.

"Physicians demand large improvements in efficacy," said Vickie Lai,analyst at Decision Resources. "A therapy that induces remission in morepatients than Remicade must induce remission in at east 40 percent ofpatients, an improvement of more than 40 percent over Remicade's rate ofinduction. Physicians do not expect a reduction in side effects, however, aslong as the agent offers greater efficacy and more convenient administration.Approximately 75 percent of respondents we surveyed for the report mandatethat a new drug be self-administered (either orally or via subcutaneousinjections)."

About Lack of Alternatives to Invasive Surgery Signals Opportunity forDrug Makers: An Acute Ulcerative Colitis Study

Lack of Alternatives to Invasive Surgery Signals Opportunity for DrugMakers: An Acute Ulcerative Colitis Study covers the current and future stateof the acute ulcerative colitis drug market. The report includes thefollowing:

The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More than 3,000 physician responses that define drug attributes driving prescription now and in the future. -- Clinical end point tradeoffs that are most influential to physicians. -- Areas of unmet need with highest potential. -- Benchmark trial results for specific drug opportunities. -- Patient share potential for emerging therapies and target product profiles. -- Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. -- Promotion: DTC spend, detailing intensity. -- Reimbursement: formulary tier, prior approval restriction, quantity limits. -- Labeling: black box warnings, approved patient segments, contraindications. -- Competition: order of entry, pricing, generic entry, pipeline sales forecast. -- Medical practice: decision trees, treating physician type, line of therapy. -- Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. -- Analysis and supporting data that identify the clinical "Gold Standard" now and over the next ten years. -- Key insights as to which clinical end points have the greatest influence on physician decision-making.

SOURCE Decision Resources, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Partnership for a Drug-Free America and Fairfax Co...
S
National Cervical Cancer Coalition to Host First A...